The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

A California town is being infested by fierce, potentially lethal fire ants which can inflict extremely painful stings and leave agonizing pustules on the skin. These ants, described by Santa Barbara ...

Imsidolimab is an investigational humanized IgG4 antibody that inhibits the function of the interleukin-36 receptor. Findings from two phase 3 trials showed skin clearance was achieved and maintained ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...